Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: A pilot study

Table 1 Subject Characteristics

Characteristic	Number of Subjects
	TACE-O	TACE-BEV
Total	15	15
Median Age (Range)	[58 (49-75)]	[61 (50-79)]
Gender
Male	12	13
Female	3	2
ECOG Performance Status
0	13	11
1	2	4
Child-Pugh Class
A	15	13
B	0	2
Underlying Liver Disease^a,b
Hepatitis B	2	4
Hepatitis C	9	7
Ethanol-Related	4	1
Cryptogenic	3	3
Hemachromatosis	0	1
Median (Range) Baseline Labs
AFP, ng/mL	[14.9 (1.8-42,550)]	[360 (1.7-9,097)]
Total Bilirubin, mg/dL	[0.9 (0.6-1.4)]	[1.1 (0.5-1.7)]
Albumin, mg/dL	[4 (2.9-4.4)]	[3.7 (2.8-4.4)]
Tumor Characteristics
Mean Tumor Burden^c, cm (± SD)	[7.4 (± 2.9)]	[6.5 (± 2.0)]
Multifocal Tumor	4	4
Vascular Invasion	1	0
BCLC Stage
A	3	1
B	10	10
C^d	2	4
Previous Anti-Cancer Therapy
Resection Alone	1	0
Resection and TACE	0	1
None	14	14

^a On the TACE-O arm, 2 subjects had hepatitis C and ethanol-related disease, and 1 subject had hepatitis B and C co-infection.
^b On the TACE-BEV arm, 1 subject had hepatitis C and hemachromatosis.
^c Tumor burden defined as the sum of the longest unidimensional measurements.
^d All subjects with BCLC stage C disease were characterized as stage C due to an ECOG PS of 1.

ISSN: 1471-2407